| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
|
| [2] |
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun (Lond), 2021, 41(10): 1037-1048.
|
| [3] |
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164.
|
| [4] |
Rosati G, Aprile G, Colombo A, et al. Colorectal cancer heterogeneity and the impact on precision medicine and therapy efficacy[J]. Biomedicines, 2022, 10(5): 1035.
|
| [5] |
Zhuo X, Guo H, Ma J, et al. Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations[J]. J Cancer Res Clin Oncol, 2023, 149(5): 2029-2039.
|
| [6] |
Zhou C, Li X, Wang Q, et al. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase Ⅱ study[J]. J Clin Oncol, 2020, 38(24): 2753-2761.
|
| [7] |
Gan K, Gao Y, Liu K, et al. The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis[J]. Frontiers in Oncology, 2021, 11: 653491.
|
| [8] |
Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer[J]. Ann Oncol, 2018, 29(5): 1108-1119.
|
| [9] |
Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3[J]. Cancer, 2018, 124(7): 1358-1373.
|
| [10] |
Chen Z, Chen J, Gao Y, et al. Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer[J]. Expert Rev Anticancer Ther, 2021, 21(10): 1097-1104.
|
| [11] |
Gao M, Jiang T, Li P, et al. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis[J]. Pharmacol Res, 2022, 182: 106330.
|
| [12] |
Strickler JH, Yoshino T, Graham RP, et al. Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: a review[J]. JAMA Oncology, 2022, 8(5): 760-769.
|
| [13] |
Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2019, 20(4): 518-530.
|
| [14] |
Nakamura Y, Okamoto W, Kato T, et al. TRIUMPH: Primary efficacy of a phase Ⅱ trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study[J]. Ann Oncol, 2019, 30: v199-v200.
|
| [15] |
Strickler JH, Zemla T, Ou FS, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial[J]. Ann Oncol, 2019, 30: v200.
|
| [16] |
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(6): 738-746.
|
| [17] |
Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial[J]. ESMO Open, 2020, 5(5): e000911.
|
| [18] |
Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 779-789.
|
| [19] |
Nakamura Y, Sawada K, Fujii S, et al. HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer[J]. ESMO Open, 2019, 4(3): e000530.
|
| [20] |
Cen S, Liu Z, Pan H, et al. Clinicopathologic features and treatment advances in cancers with HER2 alterations[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188605.
|
| [21] |
El-Deiry WS, Goldberg RM, Lenz HJ, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019[J]. CA Cancer J Clin, 2019, 69(4): 305-343.
|
| [22] |
Robichaux JP, Elamin YY, Vijayan RSK, et al. Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity[J]. Cancer Cell, 2019, 36(4): 444-457. e447.
|
| [23] |
Guarini C, Grassi T, Pezzicoli G, et al. Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer[J]. Int J Mol Sci, 2021, 22(13): 6813.
|
| [24] |
Sun SJ, Lin Q, Sun Q, et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer[J]. J Cancer Res Ther, 2016, 12(1): 323-333.
|
| [25] |
Wang G, He Y, Sun Y, et al. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer[J]. Clin Transl Oncol, 2020, 22(6): 813-822.
|
| [26] |
Li QH, Wang YZ, Tu J, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance[J]. Gastroenterol Rep (Oxf), 2020, 8(3): 179-191.
|
| [27] |
Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer[J]. The Oncologist, 2019, 24(10): 1395-1402.
|
| [28] |
Sawada K, Nakamura Y, Yamanaka T, et al. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2018, 17(3): 198-205.
|
| [29] |
Jeong JH, Kim J, Hong YS, et al. HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF[J]. Clin Colorectal Cancer, 2017, 16(3): e147-e152.
|
| [30] |
Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment[J]. Cancer Discovery, 2015, 5(8): 832-841.
|
| [31] |
De Cuyper A, Van Den Eynde M, Machiels JP. HER2 as a predictive biomarker and treatment target in colorectal cancer[J]. Clin Colorectal Cancer, 2020, 19(2): 65-72.
|
| [32] |
Laurent-Puig P, Balogoun R, Cayre A, et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)[J]. Ann Oncol, 2016, 27(Suppl. 6): vi151.
|
| [33] |
Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3 256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials[J]. J Pathol, 2016, 238(4): 562-570.
|
| [34] |
Ma CX, Bose R, Gao F, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer[J]. Clin Cancer Res, 2017, 23(19): 5687-5695.
|
| [35] |
Oaknin A, Friedman CF, Roman LD, et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial[J]. Gynecol Oncol, 2020, 159(1): 150-156.
|
| [36] |
Iwama E, Zenke Y, Sugawara S, et al. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations[J]. Eur J Cancer, 2022, 162: 99-106.
|
| [37] |
Le X, Cornelissen R, Garassino M, et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial[J]. J Clin Oncol, 2022, 40(7): 710-718.
|
| [38] |
Mazieres J, Lafitte C, Ricordel C, et al. Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial[J]. J Clin Oncol, 2022, 40(7): 719-728.
|
| [39] |
Wang C, Fakih M. Response to trastuzumab and lapatinib in a metastatic colorectal cancer harboring HER2 amplification and HER2 S310F mutation[J]. J Natl Compr Canc Netw, 2021, 19(6): 670-674.
|